- |||||||||| ACT-03 / Accure Therap
Incubation of depression: stress and the extracellular matrix (Hall E1 [IN-PERSON, ONLINE]) - Jul 23, 2022 - Abstract #ECNP2022ECNP_403; Repeated injection was indeed able to prevent the initial stress-induced cognitive deficit. This suggests that ECM remodeling serves as a substrate in mediating stress-induced effects and that balanced ECM levels are vital for optimal memory processing.
- |||||||||| Trial completion date, Trial primary completion date: ACUITY: OCS-05 in Patients With Acute Optic Neuritis (clinicaltrials.gov) - Feb 24, 2022
P2, N=36, Recruiting, PREP modulation by ACT-02 improves PD neurodegeneration via multiple mechanisms in the Line 61 a-syn transgenic model, and therefore has potential therapeutic value for disease modifying treatment of PD. Trial completion date: Dec 2022 --> Mar 2024 | Trial primary completion date: Aug 2021 --> Oct 2023
- |||||||||| ACT-01 / Accure Therap
Journal: Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation. (Pubmed Central) - Jun 29, 2020 In vivo, BN201 prevents axonal and neuronal loss, and it promotes remyelination in models of multiple sclerosis, chemically induced demyelination, and glaucoma. In summary, we provide a new promising strategy to promote neuroaxonal survival and remyelination, potentially preventing disability in brain diseases.
- |||||||||| ACT-01 / Accure Therap
Trial completion: BN201 SAD MAD Study in Healthy Subjects (clinicaltrials.gov) - Apr 10, 2019 P1, N=48, Completed, It is also suggested that robustness not at the maximum level of translation is the selection target during evolution of WYMV RNA1. Recruiting --> Completed
|